Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypoxanthine SCHEMBL30633160 | 1.00 | LMNA (0.33) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Hypoxanthine SCHEMBL17924978 | 0.89 | CYP1A2 (0.32) | BCL2MCL1PARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11903082 | 0.77 | CYP3A4 (0.34) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL385841 | 0.76 | PI4KA (0.45) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL8110 | 0.74 | PI4KA (0.48) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL3416954 | 0.74 | PI4KA (0.48) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10285464 | 0.74 | PI4KA (0.34) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL3414603 | 0.74 | PI4KA (0.48) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Adenine SCHEMBL3413247 | 0.74 | PI4KA (0.48) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3313637 | 0.74 | HRH2 (0.34) | LMNAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808157-B | Preparation method of adenosine bulk drug | 北京先通国际医药科技股份有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-114796522-A | Novel anti-tumor nano-drug for amplifying oxidative stress of targeted mitochondria | 宁波大学 | 2022-07-29 | — | — | CN | claimed |
| CN-111514352-A | Sterilization biological indication kit and sterilization biological indication method | 湖州一控医疗科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-110731352-A | Jatropha curcas extract insecticidal sustained-release gel and preparation method thereof | 凉山德农生物能源股份有限公司 | 2020-01-31 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-20080214551-A1 | Treatment of Burns | AQ+ PLC (GB) | 2008-09-04 | — | — | US | claimed |
| US-20080177075-A1 | Compositions For Progeny Gender Control | AQ+PLC STEPHEN MABBOTT ASSOCIATES (GB) | 2008-07-24 | — | — | US | claimed |
| US-20080039508-A1 | Treatment Of Tumours | AQ+PLC (GB) | 2008-02-14 | — | — | US | claimed |
| EP-1879576-A1 | USE OF A METAL ION CHELATING AGENT FOR THE TREATMENT OF ANIMAL AND HUMAN PARASITES | AQ+ PLC (GB) | 2008-01-23 | — | — | EP | claimed |
| EP-1771172-A2 | TREATMENT OF TUMOURS | AQ+ PLC (GB) | 2007-04-11 | — | — | EP | claimed |
| EP-0394346-A4 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | US HEALTH (US) | 1991-12-11 | — | — | EP | claimed |
| EP-0420868-A1 | METHOD OF FOR REDUCING WEAR ON SURFACES SUBJECTED TO FRICTIONAL FORCES. | BRITISH TECH GROUP (GB) | 1991-04-10 | — | — | EP | claimed |
| EP-0394346-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1990-10-31 | — | — | EP | claimed |
| WO-1989011518-A2 | METHOD OF AND COMPOSITIONS FOR REDUCING WEAR ON SURFACES SUBJECTED TO FRICTIONAL FORCES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-11-30 | — | — | WO | claimed |
| WO-1989006235-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-07-13 | — | — | WO | claimed |
| EP-0306845-A2 | Medicinal preparation containing certain derivatives of 6-mercaptopurine, use of these derivatives of 6-mercaptopurine, process for the preparation of the medicinal preparation and some derivatives of 6-mercaptopurine and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-15 | — | — | EP | claimed |
| EP-0077460-B1 | PURINE COMPOUNDS ENDOWED WITH IMMUNOMODULATING ACTIVITY | CO PHARMA CORPORATION S.r.l. (IT) | 1986-10-15 | — | — | EP | claimed |
| EP-0077460-A2 | Purine compounds endowed with immunomodulating activity | CO PHARMA CORPORATION S.r.l. (IT) | 1983-04-27 | — | — | EP | claimed |
| EP-0009154-B1 | COMPLEXES OF 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITIONS CONTAINING THE COMPLEXES AS ACTIVE INGREDIENTS | Newport Pharmaceuticals International, Inc. (US) | 1982-12-08 | — | — | EP | claimed |
| EP-0009154-A1 | Complexes of 9-hydroxyalkyl-purines, processes for preparing them and therapeutical compositions containing the complexes as active ingredients | Newport Pharmaceuticals International, Inc. (US) | 1980-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | LMNA 599/4885PI4KA 2349/4885PI4K2B 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.